Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals (NASDAQ: ZNTL), a clinical-stage biopharmaceutical company developing WEE1 inhibitor treatments for ovarian cancer and other tumors, has granted inducement stock options to a new employee. The Compensation Committee approved non-qualified stock options to purchase 14,000 shares of common stock under the company's 2022 Employment Inducement Incentive Award Plan.
The stock options were granted at an exercise price of $1.45 per share, matching Zentalis' closing price on the grant date. These options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, contingent on continued employment.
Zentalis Pharmaceuticals (NASDAQ: ZNTL), un'azienda biofarmaceutica in fase clinica che sviluppa trattamenti inibitori di WEE1 per il cancro ovarico e altri tumori, ha concesso opzioni azionarie di incentivo a un nuovo dipendente. Il Comitato per la Remunerazione ha approvato opzioni azionarie non qualificate per l'acquisto di 14.000 azioni ordinarie nell'ambito del Piano di Incentivi per l'Assunzione 2022 dell'azienda.
Le opzioni azionarie sono state concesse a un prezzo di esercizio di 1,45 dollari per azione, corrispondente al prezzo di chiusura di Zentalis alla data di concessione. Queste opzioni hanno una durata di 10 anni e maturano in quattro anni, con il 25% che matura dopo il primo anno e il restante 75% che matura mensilmente nei successivi tre anni, subordinatamente al mantenimento del rapporto di lavoro.
Zentalis Pharmaceuticals (NASDAQ: ZNTL), una empresa biofarmacéutica en etapa clínica que desarrolla tratamientos inhibidores de WEE1 para el cáncer de ovario y otros tumores, ha otorgado opciones sobre acciones como incentivo a un nuevo empleado. El Comité de Compensación aprobó opciones sobre acciones no calificadas para comprar 14,000 acciones ordinarias bajo el Plan de Incentivos por Contratación 2022 de la compañía.
Las opciones sobre acciones se otorgaron a un precio de ejercicio de $1.45 por acción, igualando el precio de cierre de Zentalis en la fecha de concesión. Estas opciones tienen un plazo de 10 años y se consolidan en cuatro años, con un 25% consolidado después del primer año y el 75% restante consolidado mensualmente durante los siguientes tres años, condicionado a la continuidad en el empleo.
Zentalis Pharmaceuticals (NASDAQ: ZNTL)는 난소암 및 기타 종양 치료를 위한 WEE1 억제제 개발 중인 임상 단계 바이오제약 회사로, 신입 직원에게 유인 주식 옵션을 부여했습니다. 보상 위원회는 회사의 2022년 고용 유인 인센티브 계획에 따라 14,000주의 보통주를 매수할 수 있는 비자격 주식 옵션을 승인했습니다.
주식 옵션은 부여일 종가인 주당 1.45달러의 행사가격으로 부여되었으며, 10년 만기이고 4년에 걸쳐 권리가 취득됩니다. 첫 해 후 25%가 취득되고, 나머지 75%는 이후 3년 동안 매월 취득되며 계속 고용 상태를 조건으로 합니다.
Zentalis Pharmaceuticals (NASDAQ : ZNTL), une société biopharmaceutique en phase clinique développant des traitements inhibiteurs de WEE1 pour le cancer de l'ovaire et d'autres tumeurs, a accordé des options d'achat d'actions incitatives à un nouvel employé. Le comité de rémunération a approuvé des options d'achat d'actions non qualifiées pour l'achat de 14 000 actions ordinaires dans le cadre du plan d'incitation à l'emploi 2022 de la société.
Les options d'achat d'actions ont été attribuées à un prix d'exercice de 1,45 $ par action, correspondant au cours de clôture de Zentalis à la date d'attribution. Ces options ont une durée de 10 ans et seront acquises sur quatre ans, avec 25 % acquis après la première année et les 75 % restants acquis mensuellement au cours des trois années suivantes, sous réserve de la poursuite de l'emploi.
Zentalis Pharmaceuticals (NASDAQ: ZNTL), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das WEE1-Inhibitoren zur Behandlung von Eierstockkrebs und anderen Tumoren entwickelt, hat einem neuen Mitarbeiter Anreiz-Aktienoptionen gewährt. Der Vergütungsausschuss genehmigte nicht qualifizierte Aktienoptionen zum Kauf von 14.000 Stammaktien im Rahmen des Anreizplans für Neueinstellungen 2022 des Unternehmens.
Die Aktienoptionen wurden zu einem Ausübungspreis von 1,45 USD pro Aktie gewährt, entsprechend dem Schlusskurs von Zentalis am Tag der Gewährung. Diese Optionen haben eine Laufzeit von 10 Jahren und werden über vier Jahre unverfallbar, wobei 25 % nach dem ersten Jahr und die restlichen 75 % monatlich über die folgenden drei Jahre unverfallbar werden, vorbehaltlich einer fortgesetzten Beschäftigung.
- None.
- None.
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on May 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company’s common stock to one (1) newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
Vesting of the stock options is subject to the employee’s continued service to Zentalis on each vesting date.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
For more information, please visit www.zentalis.com. Follow Zentalis on X/Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
Contacts:
Haibo Wang – Chief Business Officer
Ron Moldaver – Investor Relations
ir@zentalis.com
FAQ
What stock options did Zentalis (ZNTL) grant to its new employee in May 2025?
What is the vesting schedule for ZNTL's May 2025 inducement stock options?
What is Zentalis Pharmaceuticals' main drug development focus?
How long is the term of ZNTL's May 2025 inducement stock options?
